Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citicoline (cytidine 5'-diphosphocholine) is a naturally occurring endogenous nucleoside that serves as a critical intermediate in the biosynthesis of structural phospholipids in cell membranes, particularly phosphatidylcholine. Upon administration, citicoline is hydrolyzed into cytidine and choline, which cross the blood-brain barrier and are resynthesized into citicoline in the brain. Its neuroprotective mechanism involves the preservation of sphingomyelin and cardiolipin, the restoration of Na+/K+-ATPase activity, and the inhibition of phospholipase A2, which reduces the release of arachidonic acid and subsequent inflammatory mediators. Clinically, it is utilized for the treatment of acute stroke, traumatic brain injury, and cognitive impairment associated with neurodegenerative diseases like Alzheimer's. In many jurisdictions, it is regulated as a pharmaceutical drug, while in others, such as the United States, it is primarily marketed as a dietary supplement for cognitive enhancement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citicoline.